Literature DB >> 11435899

Vascular endothelial growth factor promotes proliferation and migration of cavernous smooth muscle cells.

X Liu1, C S Lin, T Graziottin, J Resplande, T F Lue.   

Abstract

PURPOSE: We investigated whether cavernous smooth muscle cells secrete vascular endothelial growth factor (VEGF), how they respond to VEGF and how age affects their ability to secrete and respond to VEGF.
MATERIALS AND METHODS: Corpus cavernous tissues were isolated from rats of various ages and grown as monolayer cell cultures. Smooth muscle identity was determined by immunofluorescence staining. Secreted VEGF was measured with a VEGF enzyme-linked immunosorbent assay kit. Cell proliferation was assayed with a cell titer kit. Cell migration was measured with Transwell chambers. VEGF receptor (VEGFR) messenger RNA and proteins were identified by reverse transcription-polymerase chain reaction and immunoblotting, respectively.
RESULTS: Cavernous smooth muscle cells from young (age 1 week) and old (age 28 months) rats secreted the least amounts of VEGF and those from 16-week-old rats secreted the most. VEGF stimulated the growth of cavernous smooth muscle cells at an optimal concentration of 12.5 ng./ml. At this concentration cavernous smooth muscle cells from 11-week-old and 28-month-old rats showed the highest and lowest growth rates, respectively. The optimal VEGF concentration for cavernous smooth muscle cell migration was 10 ng./ml. At this concentration cells from 4-week-old and 28-month-old rats showed the highest and lowest migratory rates, respectively. The expression of VEGFR-1 appeared to parallel the VEGF regulated growth rates of these cells. VEGFR-2 was undetectable in cavernous smooth muscle cells.
CONCLUSIONS: Cavernous smooth muscle cells from rats of different ages secreted different amounts of VEGF and showed different abilities to respond to VEGF. Cavernous smooth muscle cells responded to VEGF in terms of cell proliferation and migration. Cavernous smooth muscle cells from rats of different ages expressed different levels of VEGFR-1 but did not express VEGFR-2.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11435899

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  6 in total

Review 1.  [Pathophysiology and rehabilitation of erectile dysfunction after nerve-sparing radical prostatectomy].

Authors:  C van der Horst; F J Martinez-Portillo; K P Jünemann
Journal:  Urologe A       Date:  2005-06       Impact factor: 0.639

2.  Energy restriction and exercise modulate angiopoietins and vascular endothelial growth factor expression in the cavernous tissue of high-fat diet-fed rats.

Authors:  Inês Tomada; Nuno Tomada; Henrique Almeida; Delminda Neves
Journal:  Asian J Androl       Date:  2011-12-05       Impact factor: 3.285

3.  Anti-inflammatory and anti-fibrotic effects of annexin1 on erectile function after cavernous nerve injury in rats.

Authors:  F N Facio; M F Facio; L F Spessoto; D Pessutti; L O Reis; S G Campos; S Taboga
Journal:  Int J Impot Res       Date:  2016-08-25       Impact factor: 2.896

4.  Dual growth factor-loaded in situ gel-forming bulking agent: passive and bioactive effects for the treatment of urinary incontinence.

Authors:  Se Heang Oh; Jin Woo Bae; Jun Goo Kang; In Gul Kim; Joo Young Son; Ji Youl Lee; Ki Dong Park; Jin Ho Lee
Journal:  J Mater Sci Mater Med       Date:  2015-01-13       Impact factor: 3.896

5.  Endothelial function of von Hippel-Lindau tumor suppressor gene: control of fibroblast growth factor receptor signaling.

Authors:  Kristen J Champion; Maria Guinea; Vincent Dammai; Tien Hsu
Journal:  Cancer Res       Date:  2008-06-15       Impact factor: 12.701

6.  Knockdown of miR-423-5p simultaneously upgrades the eNOS and VEGFa pathways in ADSCs and improves erectile function in diabetic rats.

Authors:  Jun Zhou; Yinghao Yin; Yuan Yang; Dongyi Peng; Jingchao Wei; Guangming Yin; Yuxin Tang
Journal:  J Cell Mol Med       Date:  2021-09-20       Impact factor: 5.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.